DYAI - Dyadic International Inc., DE
IEX Last Trade
1.35
-0.020 -1.481%
Share volume: 32,605
Last Updated: Fri 30 Aug 2024 09:56:40 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.37
-0.02
-1.46%
Fundamental analysis
24%
Profitability
25%
Dept financing
7%
Liquidity
74%
Performance
15%
Performance
5 Days
-7.58%
1 Month
-2.90%
3 Months
-40.97%
6 Months
-4.96%
1 Year
-29.10%
2 Year
-50.19%
Key data
Stock price
$1.35
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.13 - $2.67
52 WEEK CHANGE
-$0.30
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO:
Region: US
Website: dyadic.com
Employees: 47
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: dyadic.com
Employees: 47
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
dyadic international, inc. (otcqx: dyai) - we are a global biotechnology company focused on further improving and leveraging the patented and proprietary c1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.
Recent news